PAR 13.0% 52.0¢ paradigm biopharmaceuticals limited..

Osteoarthritis medicine, page-26

  1. 7 Posts.
    So, wintervet, what are the side effects humans face that the dogs and horses don’t? I found a paper from Japan published in 2010 (pdf available free here https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873929/ ) where they found that weekly subcutaneous injection of PPS at the dose PAR plan on using was painful in 30% of OA patients and there was bruising at the injection site in 20%. They used the Bene PPS, same as PAR will be using. The Japanese elected not to pursue development and marketing of PPS – side effects is probably one reason. Also, there are lots of products already on market that temporarily reduce pain and inflammation, several without any significant side effects. Some of these are oral, not injectable and some don’t even require a prescription. The big question to answer is whether PPS fixes the underlying osteoarthritis disease or at least stops disease progression. I presume PAR will need MRI scans in its next clinical trial to compare actual disease in treated vs control groups. Nothing to get excited about until we see whether the trial results in 2019 actually show disease improvement, not just temporary pain relief. We know injectable products for humans are tricky. But we won’t know whether there are other side effects from injectable PPS until 2019. Elmiron, already on market for other indications, is oral so avoids the risks of injectable PPS – maybe a better bet in the long run? What do you think?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
52.0¢
Change
0.060(13.0%)
Mkt cap ! $82.30M
Open High Low Value Volume
47.0¢ 56.0¢ 40.0¢ $4.475M 8.971M

Buyers (Bids)

No. Vol. Price($)
1 12150 49.0¢
 

Sellers (Offers)

Price($) Vol. No.
52.0¢ 39994 1
View Market Depth
Last trade - 16.10pm 26/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.